COPDCompEx: A novel composite endpoint for COPD exacerbations to enable faster clinical development

Area of Science:

• Pulmonary Medicine
• Clinical Trial Design
• Biostatistics

Background:

• Evaluating moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations in clinical trials is crucial but requires large, lengthy studies.
• The need for more efficient trial designs to assess COPD exacerbation treatments is evident.

Purpose of the Study:

• To develop and validate a novel composite endpoint, COPDCompEx, for predicting treatment effects on COPD exacerbations.
• To enable the design of shorter, more patient-efficient early-phase clinical trials.

Main Methods:

• A post hoc analysis of data from 20 randomized controlled trials was conducted.
• COPDCompEx was developed by incorporating diary events, moderate/severe exacerbations, and study dropouts.
• The performance of COPDCompEx was compared against exacerbations alone in terms of event frequency, treatment effect, and sample size reduction.

Main Results:

• COPDCompEx events were over three times more frequent than exacerbations alone at 3 months.
• Treatment effects observed with COPDCompEx closely mirrored those of exacerbations.
• The use of COPDCompEx significantly increased statistical power, substantially reducing the required sample size for trials.

Conclusions:

• COPDCompEx serves as a reliable predictor of treatment effects on moderate and severe COPD exacerbations.
• This composite endpoint facilitates the design of shorter Phase 2 trials, reducing patient burden and accelerating decision-making.
• COPDCompEx offers a more efficient approach compared to traditional exacerbation endpoints, particularly for early-phase research.